BR112021025236A2 - Composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou o tratamento de fibrose, distúrbios dermatológicos, dor, doenças proliferativas malignas, benignas, doenças respiratórias, distúrbios do sistema nervoso central, doenças cardiovasculares, distúrbios inflamatórios, obesidade ou resistência à insulina - Google Patents

Composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou o tratamento de fibrose, distúrbios dermatológicos, dor, doenças proliferativas malignas, benignas, doenças respiratórias, distúrbios do sistema nervoso central, doenças cardiovasculares, distúrbios inflamatórios, obesidade ou resistência à insulina

Info

Publication number
BR112021025236A2
BR112021025236A2 BR112021025236A BR112021025236A BR112021025236A2 BR 112021025236 A2 BR112021025236 A2 BR 112021025236A2 BR 112021025236 A BR112021025236 A BR 112021025236A BR 112021025236 A BR112021025236 A BR 112021025236A BR 112021025236 A2 BR112021025236 A2 BR 112021025236A2
Authority
BR
Brazil
Prior art keywords
compound
disorders
diseases
pharmaceutical composition
prophylaxis
Prior art date
Application number
BR112021025236A
Other languages
English (en)
Inventor
Christine Brotschi
Cyrille Lescop
Martin Bolli
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of BR112021025236A2 publication Critical patent/BR112021025236A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

composto, composição farmacêutica, e, uso do composto. a presente invenção se refere aos derivados de piridin-3-ila de fórmula (i) em que r1, r2, r3, r4, r5, ar1, l, m e n são como descritos na descrição, à preparação deles, aos sais farmaceuticamente aceitáveis dos mesmos, e ao uso deles como fármacos, às composições farmacêuticas que contêm um ou mais compostos de fórmula (i), e especialmente ao uso deles como moduladores de receptor de lpa1.
BR112021025236A 2019-06-18 2020-06-17 Composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou o tratamento de fibrose, distúrbios dermatológicos, dor, doenças proliferativas malignas, benignas, doenças respiratórias, distúrbios do sistema nervoso central, doenças cardiovasculares, distúrbios inflamatórios, obesidade ou resistência à insulina BR112021025236A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2019065963 2019-06-18
PCT/EP2020/066767 WO2020254408A1 (en) 2019-06-18 2020-06-17 Pyridin-3-yl derivatives

Publications (1)

Publication Number Publication Date
BR112021025236A2 true BR112021025236A2 (pt) 2022-02-01

Family

ID=71105482

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025236A BR112021025236A2 (pt) 2019-06-18 2020-06-17 Composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou o tratamento de fibrose, distúrbios dermatológicos, dor, doenças proliferativas malignas, benignas, doenças respiratórias, distúrbios do sistema nervoso central, doenças cardiovasculares, distúrbios inflamatórios, obesidade ou resistência à insulina

Country Status (15)

Country Link
US (1) US20220251068A1 (pt)
EP (1) EP3986884A1 (pt)
JP (1) JP7494222B2 (pt)
KR (1) KR20220020921A (pt)
CN (1) CN114026082B (pt)
AR (1) AR119162A1 (pt)
AU (1) AU2020298014A1 (pt)
BR (1) BR112021025236A2 (pt)
CA (1) CA3143618A1 (pt)
CL (1) CL2021003348A1 (pt)
IL (1) IL288950A (pt)
MA (1) MA56504A (pt)
MX (1) MX2021015727A (pt)
SG (1) SG11202111162PA (pt)
WO (1) WO2020254408A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114761001A (zh) * 2019-12-04 2022-07-15 爱杜西亚药品有限公司 氮杂环丁烷lpa1受体拮抗剂与抗纤维化药剂的组合

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364659B1 (en) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US20070078120A1 (en) 2003-10-21 2007-04-05 Hitoshi Ban Novel piperidine derivative
CN1878551A (zh) 2003-11-12 2006-12-13 默克公司 4－苯基哌啶磺酰基甘氨酸转运体抑制剂
EP1687296A1 (en) 2003-11-18 2006-08-09 Warner-Lambert Company LLC Antibacterial aminoquinazolidinedione derivatives
CN101198590B (zh) 2005-08-24 2012-05-09 卫材R&D管理有限公司 吡啶衍生物及嘧啶衍生物（3）
JP5164510B2 (ja) 2006-10-06 2013-03-21 日本曹達株式会社 含窒素複素環化合物および有害生物防除剤
ATE552257T1 (de) 2007-10-18 2012-04-15 Merck Sharp & Dohme Positive allosterische chinolizidinon-m1- rezeptormodulatoren
MX344077B (es) 2008-05-05 2016-12-05 Sanofi - Aventis Derivados de ácido ciclopentanocarboxílico condensados sustituidos con acilamino y su uso como productos farmacéuticos.
TW201117809A (en) * 2009-09-25 2011-06-01 Astellas Pharma Inc Substituted amide compounds
CN103270036B (zh) 2010-08-05 2015-11-25 佐蒂斯有限责任公司 作为抗寄生物剂的异噁唑啉衍生物
TW201305178A (zh) 2010-10-29 2013-02-01 Glenmark Pharmaceuticals Sa 作為ｍＰＧＥＳ－１抑制物的三環化合物
AU2011338417B2 (en) 2010-12-07 2016-12-01 Amira Pharmaceuticals, Inc. Polycyclic LPA1 antagonist and uses thereof
CN103517907B (zh) 2011-03-10 2016-07-06 硕腾服务有限责任公司 作为抗寄生物剂的螺环异噁唑啉衍生物
BR112014014909A2 (pt) 2011-12-21 2017-06-13 Ardelyx Inc agonistas de tgr5 não sistêmicos
WO2014160017A1 (en) * 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors
CN105849097A (zh) 2013-11-06 2016-08-10 百时美施贵宝公司 取代的吡啶衍生物用作gsk-3抑制剂
EP3802517B1 (en) 2018-06-07 2022-12-21 Idorsia Pharmaceuticals Ltd Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis

Also Published As

Publication number Publication date
WO2020254408A1 (en) 2020-12-24
CN114026082A (zh) 2022-02-08
CN114026082B (zh) 2024-06-07
MX2021015727A (es) 2022-01-24
EP3986884A1 (en) 2022-04-27
CA3143618A1 (en) 2020-12-24
SG11202111162PA (en) 2021-11-29
TW202115011A (zh) 2021-04-16
AU2020298014A1 (en) 2022-02-10
JP2022537177A (ja) 2022-08-24
IL288950A (en) 2022-02-01
MA56504A (fr) 2022-04-27
AR119162A1 (es) 2021-12-01
KR20220020921A (ko) 2022-02-21
CL2021003348A1 (es) 2022-09-23
JP7494222B2 (ja) 2024-06-03
US20220251068A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
BR112016023679A2 (pt) derivados de amida e sais farmaceuticamente aceitáveis dos mesmos, método de preparação dos mesmos e aplicação medicinal dos mesmos
BR112021017408A2 (pt) Compostos tricíclicos fundidos úteis como agentes anticancerosos
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
BR112015032623A8 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
BR112018006448A2 (pt) derivado de oxaespiro, método de preparação dos mesmos, e aplicações dos mesmos em medicamentos
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
MY195194A (en) Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors
BR112017023764A2 (pt) derivados de ciclohexano substituído por amido
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
BRPI0709680B8 (pt) derivados de pirrol, tiofeno e furano substituídos por piridil e piridimil como inibidores de quinase
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
BR112018069601A2 (pt) derivados de indolina substituídos como inibidores da replicação viral da dengue
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
PH12019500188A1 (en) Piperidine cxcr7 receptor modulators
BR112017010645A2 (pt) derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos
PH12019502562A1 (en) N-substituted indole derivatives
PH12019501724A1 (en) Estrogen receptor modulators
BR112022013322A2 (pt) Derivado de tetra-hidroisoquinolina tricíclico, método de preparação para o mesmo e aplicação do mesmo em medicina
BR112022005660A2 (pt) Inibidores de fxia e método de preparação dos mesmos e uso farmacêutico dos mesmos.
BR112021025236A2 (pt) Composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou o tratamento de fibrose, distúrbios dermatológicos, dor, doenças proliferativas malignas, benignas, doenças respiratórias, distúrbios do sistema nervoso central, doenças cardiovasculares, distúrbios inflamatórios, obesidade ou resistência à insulina
EA201992804A1 (ru) Производные аминогликозида и их применение при лечении генетических заболеваний